Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Checkmate Pharmaceuticals, Inc. (CMPI) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/31/2022 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF",
"CHECKMATE PHARMACEUTICALS, INC."
05/12/2022 8-K Quarterly results
04/19/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Checkmate Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and Scandinavian Acquisition Sub, Inc",
"Tender and Support Agreement, by and among Regeneron Pharmaceuticals, Inc., Scandinavian Acquisition Sub, Inc. and certain Stockholders of Checkmate Pharmaceuticals, Inc"
04/19/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer Tarrytown, N.Y. and Cambridge, Mass., April 19, 2022 - Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc. a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the im..."
03/01/2022 8-K Quarterly results
02/09/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Executive Employment Agreement between Checkmate Pharmaceuticals, Inc. and Alan Bash",
"Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO"
02/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors January 31, 2022 CAMBRIDGE, Mass., Jan. 31, 2022 — Checkmate Pharmaceuticals, Inc . , a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors . “Jon is a well-respected physician-scientist and drug development expert. With his diverse background, he has driven numerous clinical stage immuno-oncology development portfolios,” said Alan Fuhrman, Interim CEO and President of Checkmate. “We are thrilled to strengthen Checkmate's Board by leveraging Jon's broad experience across academia, government and the biopharmaceutical indu..."
12/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D."
12/14/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update"
10/27/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Separation Agreement and Release between Checkmate Pharmaceuticals, Inc. and Barry Labinger",
"Interim CEO Agreement between Checkmate Pharmaceuticals, Inc. and Alan Fuhrman",
"Checkmate Pharmaceuticals Announces CEO Transition"
10/04/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Slide Presentation of Checkmate Pharmaceuticals, Inc"
08/12/2021 8-K Quarterly results
Docs: "Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update"
08/04/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Slide Presentation of Checkmate Pharmaceuticals, Inc"
06/21/2021 8-K Submission of Matters to a Vote of Security Holders
05/13/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
01/05/2021 8-K Quarterly results
12/08/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab"
11/13/2020 8-K Quarterly results
Docs: "Checkmate Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides an Update on Recent Progress"
10/20/2020 8-K Quarterly results
10/05/2020 8-K Quarterly results
09/18/2020 8-K Quarterly results
Docs: "Checkmate Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides an Update on Recent Progress"
08/14/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy